MedTrace Logo

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

NCT02363621 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2019-04-26

Study results available
· View outcomes & findings →

Summary

This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of ranibizumab 0.3mg and aflibercept 2.0mg in patients with DME.

The investigators will be evaluating patients (1-7 days) post injections for:

1\. Intraocular inflammation (defined as anterior chamber and/or vitreous cells 2. Pain (as measured on a standardized pain scale).

Conditions

Interventions

DRUG

Ranibizumab 0.3 mg

Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg

DRUG

Aflibercept 2.0 mg

Patient will receive intravitreal injection of Aflibercept 2.0 mg

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Arshad Khanani

    lead OTHER

Principal Investigators

  • Arshad Khanani, MD · Sierra Eye Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02363621 on ClinicalTrials.gov